Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis (NCT06950385)
A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Patients With Familial Adenomatous Polyposis
🩺 Plain-English Summary (8th-Grade Level)
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to be answered by this trial are: * Does taking eRapa help to slow down the progression of the disease in patients with FAP? * Is eRapa a safe treatment for patients diagnosed with FAP? * What is the effect of eRapa on the number of polyps found in GI tract of patients diagnosed with FAP? * How does treatment with eRapa affect a patient's quality of life? Participants will: * Take eRapa or placebo once per day every other week until disease progresses (gets worse), stops taking part in the trial or dies. * Visit the clinic once every 3 months for check ups and tests. * Have an endoscopy at the start of the trial and then every 6 months to check on whether the disease is getting better or worse.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Arcadia, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- City of Hope — Arcadia, California
- Yale Cancer Center — New Haven, Connecticut
- Georgetown University — Washington D.C., District of Columbia
- Digestive & Liver Center of Florida — Orlando, Florida
- Cleveland Clinic Florida — Weston, Florida
- University of Chicago — Chicago, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- Johns Hopkins University — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Department of Surgery, Section of Colon Rectal and Surgery — St Louis, Missouri
- Cleveland Clinic — Cleveland, Ohio
- Ohio State University — Columbus, Ohio
- Geisinger Medical Center — Danville, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Benaroya Research Institute at Virginia Mason — Seattle, Washington
- University of Washington - Fred Hutchinson — Seattle, Washington
- Copenhagen University Hospital — Copenhagen,
- Universitätsklinikum Bonn — Bonn,
- IRCCS Ospedale San Raffaele — Milan,
- Istituto Nazionale dei Tumori — Milan,
- Amsterdam UMC — Amsterdam,
- Radboud University Medical Center — Nijmegen,
- Hospital Oncologico - Puerto Rico Medical Center — Rio Piedras,
📞 Contact the Study Coordinator
Phone: (626) 218-2570
Email: gidos@coh.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Familial Adenomatous Polyposis (FAP) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.